CRDL Cardiol Therapeutics Inc. - Class A

Cardiol Therapeutics Inc is a clinical-stage biotechnology company developing therapies for inflammatory heart disease. The company has received approval to commence a Phase II/III clinical trial investigating its product, CardiolRx, in COVID-19 patients with history of cardiovascular disease. CardiolRx is a pharmaceutically produced, GMP certified, THC free (<10 ppm) oral cannabidiol formulation.

As of 09/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Canada
Country of incorporation:  
IPO date:  01/10/2019
Outstanding shares:  62,485,291
Average volume:  338,635
Market cap:   $64,359,850
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   -9.81
PB ratio:   0.92
PS ratio:   1,050.71
Return on equity:   -41.50%
Net income %:   -40,170.45%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy